Effectiveness and safety of donepezil in hispanic patients with Alzheimer's disease: A 12-week open-label study

Journal of the National Medical Association

Volumn 100, Issue 11, 2008, Pages 1350-1358

  Lopez, Oscar L ^a   Mackell, Joan A ^b   Sun, Yijun ^c   Kassalow, Laurent M ^c   Xu, Yikang ^b   McRae, Thomas ^b   Li, Honglan ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c EISAI INC   (United States)

Author keywords

Alzheimer's disease; Drugs; Latinos

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; FEMALE; HISPANIC; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCREENING;

EID: 57149091142     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31515-7     Document Type: Article

References (43)

1. Webster's Ninth New Collegiate Dictionary. Springfield, MA: Merriam-Webster; 1991.
2. U.S.Census Bureau. U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin, March 18, 2004. www.census.gov/ipc/www/usinterimproj. Accessed 03/18/04.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
4. Jorm AF. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci. 1991;240:218-222.
5. Alzheimer's Association. Alzheimer's Disease Facts and Figures 2007. Alzheimer's Association web site. www.alz.org/ alzheimers_disease_publications_reports.asp. Accessed 02/25/08.
6. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002;23:213-231.
7. Perkins P, Annegers JF, Doody RS, et al. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997;49:44-50.
8. Tang M-X, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49-56.
9. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751-755.
10. Clark CM, DeCarli C, Mungas D, et al. Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals. Arch Neurol. 2005;62:774-778.
11. Fitten LJ, Ortiz F, Ponton M. Frequency of Alzheimer's disease and other dementias in a community outreach sample of Hispanics. J Am Geriatr Soc. 2001;49:1301-1308.
12. Campbell AK, Jagust WJ, Mungas DM, et al. Low erythrocyte folate, but not plasma vitamin B-12 or homocysteine, is associated with dementia in elderly Latinos. J Nutr Health Aging. 2005;9:39-43.
13. Baldwin CM, Bell IR, Giuliano A, et al. Differences in Mexican American and Non-Hispanic White veterans' homocysfeine levels. J Nurs Scholarsh. 2007;39:235-242.
14. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459-469.
15. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
16. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61:1852-1856.
17. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published erratum appears in: BMJ 2001;322:1456]. BMJ. 1999;318:633-638.
18. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
19. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Wall JR, Deshpande SA, MacNeill SE, et al. The Fuld Object Memory Evaluation, a useful tool in the assessment of urban geriatric patients. Clin Gerontol. 1998;19:39-49.
22. La Rue A, Romero LJ, Ortiz IE, et al. Neuropsychological performance of Hispanic and non-Hispanic older adults: an epidemiologic survey. Clin Neuropsychol. 1999;13:474-486.
23. Mast BT, Fitzgerald J, Steinberg J, et al. Effective screening for Alzheimer's disease among older African Americans. Clin Neuropsychol. 2001;15:196-202.
24. Smith A. The Symbol Digit Modalities Test: a neuropsychological test for economic screening of learning and other cerebral disorders. Learn Disord. 1968;3:83-91.
25. Fleisher AS, Sowell BB, Taylor C, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68:1588-1595.
26. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 suppl 6):S10-S16.
27. Griffith P. Lichtenberg P, Goldman R, et al. Safety and efficacy of donepezil in African Americans with mild-to-moderafe Alzheimer's disease. J Natl Med Assoc. 2006;98:1590-1597.
28. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031.
29. Colleran KM, Richards A, Shafer K. Disparities in cardiovascular disease risk and treatment: demographic comparison. J Investig Med. 2007;55:415-422.
30. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
31. Kuller LH, Lopez OL, Newman A, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:13-22.
32. Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21:57-62.
33. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
34. Cherner M, Suarez P, Lazzaretto D, et al. Demographically corrected norms for the Brief Visuospatial Memory Test-revised and Hopkins Verbal Learning Test-revised in monolingual Spanish speakers from the U.S.-Mexico border region. Arch Clin Neuropsychol. 2007;22:343-353.
35. Gonzalez HM, Mungos D, Haan MN. A semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans. Arch Clin Neuropsychol. 2005;20:199-208.
36. Fortuny L, Heafon RK, Hermosillo D. Neuropsychological comparisons of Spanish-speaking participants from the U.S.-Mexico border region versus Spain. J Int Neuropsychol Soc. 1998;4:363-379.
37. Ortiz F, Fitten LJ, Cummings JL, et al. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2006;21:263-273.
38. Hinton L, Haan M, Geller S, et al. Neuropsychiatric symptoms in Latino elders with dementia or cognitive impairment without dementia and factors that modify their association with caregiver depression. Gerontologist. 2003;43:669-677.
39. Lezak M. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995.
40. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15:346-353.
41. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483.
42. Trinh N-H, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a mefa-analysis. JAMA. 2003;289:210-216.
43. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214-219.